28 patients ont présenté une récidive post-opératoire : 3 locorégionales et 25 métastatiques. La médiane de survie sans récidive était de 17, pp.1-38 ,
Cancer statistics, 2017, CA: A Cancer Journal for Clinicians, vol.91, issue.suppl 3, pp.7-30, 2017. ,
DOI : 10.1016/j.ypmed.2016.08.015
Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline, Journal of Clinical Oncology, vol.34, issue.21, pp.2541-56, 2016. ,
DOI : 10.1200/JCO.2016.67.5553
Pancreatic Ductal Adenocarcinoma Radiology Reporting Template: Consensus Statement of the Society of Abdominal Radiology and the American Pancreatic Association, Gastroenterology, vol.146, issue.1, pp.291-304, 2014. ,
DOI : 10.1053/j.gastro.2013.11.004
Laparoscopy in the staging of pancreatic cancer, British Journal of Surgery, vol.ii, issue.3, pp.325-362, 2001. ,
DOI : 10.1016/S0140-6736(69)92326-5
Laparoscopy and laparoscopic ultrasonography in judging the resectability of pancreatic head cancer, Hepatobiliary Pancreat Dis Int HBPD INT. nov, vol.2, issue.4, pp.609-620, 2003. ,
Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy, Annals of Surgical Oncology, vol.9, issue.8 ,
DOI : 10.2214/ajr.178.4.1780821
Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of Disease, Journal of the American College of Surgeons, vol.206, issue.5, pp.833-846, 2008. ,
DOI : 10.1016/j.jamcollsurg.2007.12.020
Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology, Journal of the National Comprehensive Cancer Network, vol.15, issue.8, pp.1028-61, 2017. ,
DOI : 10.6004/jnccn.2017.0131
Redefining the R1 resection in pancreatic cancer, Br J Surg, vol.93, pp.1232-1237, 2006. ,
Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer, JAMA, vol.310, issue.14, pp.1473-81, 2013. ,
DOI : 10.1001/jama.2013.279201
URL : http://jama.jamanetwork.com/data/journals/jama/927990/joi130069.pdf
R1 resection in pancreatic cancer has significant impact on long-term outcome in standardized pathology modified for routine use, Surgery, vol.152, issue.3, pp.103-111, 2012. ,
DOI : 10.1016/j.surg.2012.05.015
Aggressive Surgery for Borderline Resectable Pancreatic Cancer, Pancreas, vol.42, issue.6, pp.1004-1014, 2013. ,
DOI : 10.1097/MPA.0b013e31827b2d7c
Pancreatic Adenocarcinoma with Venous Involvement: Is Up-Front Synchronous Portal-Superior Mesenteric Vein Resection Still Justified? A Survey of the Association Fran??aise de Chirurgie, Annals of Surgical Oncology, vol.19, issue.suppl 3, pp.1874-83, 2015. ,
DOI : 10.1245/s10434-011-2110-8
Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell, pp.362-75, 2012. ,
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer, New England Journal of Medicine, vol.364, issue.19, pp.1817-1842, 2011. ,
DOI : 10.1056/NEJMoa1011923
URL : https://hal.archives-ouvertes.fr/hal-00598658
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine, New England Journal of Medicine, vol.369, issue.18, pp.1691-703, 2013. ,
DOI : 10.1056/NEJMoa1304369
Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: A systematic review and meta-analysis of response and resection percentages, Pancreatology, vol.16, issue.1, pp.28-37, 2016. ,
DOI : 10.1016/j.pan.2015.11.007
FOLFIRINOX-Based Neoadjuvant Therapy in Borderline Resectable or Unresectable Pancreatic Cancer, Pancreas, vol.44, issue.4, pp.515-536, 2015. ,
DOI : 10.1097/MPA.0000000000000314
Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens, HPB, vol.16, issue.1, pp.20-33, 2014. ,
DOI : 10.1111/hpb.12061
Re-evaluation of classical prognostic factors in resectable ductal adenocarcinoma of the pancreas, World Journal of Gastroenterology, vol.22, issue.28, pp.6424-6457, 2016. ,
DOI : 10.1016/j.gassur.2006.09.008
Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort, Annals of Surgical Oncology, vol.11, issue.9, pp.1196-205, 2015. ,
DOI : 10.1016/S1470-2045(10)70172-8
Serum CA 19-9 Response to Neoadjuvant Therapy is Associated with Outcome in Pancreatic Adenocarcinoma, Annals of Surgical Oncology, vol.11, issue.13, pp.4351-4359, 2014. ,
DOI : 10.1111/j.1477-2574.2009.00110.x
Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma, Gastroenterology, vol.143, issue.3, pp.664-674, 2012. ,
DOI : 10.1053/j.gastro.2012.06.006
SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial, Clinical Cancer Research, vol.21, issue.21, pp.4811-4819, 2015. ,
DOI : 10.1158/1078-0432.CCR-14-3222
Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma, JNCI: Journal of the National Cancer Institute, vol.19, issue.5, 2015. ,
DOI : 10.1158/1078-0432.CCR-12-1184
Body Mass Index and Risk, Age of Onset, and Survival in Patients With Pancreatic Cancer, JAMA, vol.301, issue.24, pp.2553-62, 2009. ,
DOI : 10.1001/jama.2009.886
Hallmarks of Cancer: The Next Generation, Cell, vol.144, issue.5, pp.646-74, 2011. ,
DOI : 10.1016/j.cell.2011.02.013
Inflammation and cancer: back to Virchow?, The Lancet, vol.357, issue.9255, pp.539-584, 2001. ,
DOI : 10.1016/S0140-6736(00)04046-0
Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape, Cytokine & Growth Factor Reviews, vol.18, issue.1-2, pp.171-82, 2007. ,
DOI : 10.1016/j.cytogfr.2007.01.015
Tumor-infiltrating T lymphocytes: friends or foes?, Laboratory Investigation, vol.5, issue.Part 2, pp.231-276, 2006. ,
DOI : 10.1038/ni1029
URL : http://www.nature.com/labinvest/journal/v86/n3/pdf/3700389a.pdf
Complex role for the immune system in initiation and progression of pancreatic cancer, World Journal of Gastroenterology, vol.20, issue.32, pp.11160-81, 2014. ,
DOI : 10.1038/ni.1791
Tumor-Associated Transforming Growth Factor-?? and Interleukin-10 Contribute to a Systemic Th2 Immune Phenotype in Pancreatic Carcinoma Patients, The American Journal of Pathology, vol.155, issue.2, pp.537-584, 1999. ,
DOI : 10.1016/S0002-9440(10)65149-8
Immunodeficiency in different histotypes of radically operable gastrointestinal cancers, J Exp Clin Cancer Res CR. juin, vol.23, issue.2, pp.195-200, 2004. ,
Systemic and local immunosuppression in pancreatic cancer patients, Clin Cancer Res Off J Am Assoc Cancer Res. mars, vol.7, issue.3, pp.925-932, 2001. ,
Systemic inflammation, nutritional status and survival in patients with cancer, Current Opinion in Clinical Nutrition and Metabolic Care, vol.12, issue.3, pp.223-229, 2009. ,
DOI : 10.1097/MCO.0b013e32832a7902
Measurement of the Systemic Inflammatory Response Predicts Cancer-Specific and Non-Cancer Survival in Patients With Cancer, Nutrition and Cancer, vol.41, issue.1-2, pp.64-73, 2001. ,
DOI : 10.1080/01635581.2001.9680613
INCREASED VASCULAR PERMEABILITY: A MAJOR CAUSE OF HYPOALBUMINAEMIA IN DISEASE AND INJURY, The Lancet, vol.325, issue.8432, pp.781-785, 1985. ,
DOI : 10.1016/S0140-6736(85)91447-3
Acute-Phase Proteins and Other Systemic Responses to Inflammation, New England Journal of Medicine, vol.340, issue.6, pp.448-54, 1999. ,
DOI : 10.1056/NEJM199902113400607
Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill, Bratisl Lek Listy, vol.102, issue.1, pp.5-14, 2001. ,
Levels of Serum Cytokines and Acute Phase Proteins in Patients With Essential and Cancer-Related Thrombocytosis, American Journal of Clinical Oncology, vol.26, issue.2, pp.135-175, 2003. ,
DOI : 10.1097/00000421-200304000-00007
Involvement of platelets in tumour angiogenesis? Lancet Lond Engl, pp.1775-1782, 1998. ,
Cytokines, the Acute-Phase Response, and Resting Energy Expenditure in Cachectic Patients with Pancreatic Cancer, Annals of Surgery, vol.219, issue.4 ,
DOI : 10.1097/00000658-199404000-00001
Longitudinal study of body cell mass depletion and the inflammatory response in cancer patients, Nutrition and Cancer, vol.12, issue.2, pp.101-106, 1998. ,
DOI : 10.1016/0899-9007(95)00078-X
Longitudinal Study of Weight, Appetite, Performance Status, and Inflammation in Advanced Gastrointestinal Cancer, Nutrition and Cancer, vol.35, issue.2, pp.127-136, 1999. ,
DOI : 10.1207/S15327914NC352_5
Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer, British Journal of Cancer, vol.71, issue.Suppl 4, pp.1028-1058, 2003. ,
DOI : 10.1038/bjc.1995.212
Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer, International Journal of Colorectal Disease, vol.47, issue.8 Suppl, pp.881-887, 2007. ,
DOI : 10.7326/0003-4819-133-8-200010170-00015
Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer, British Journal of Cancer, vol.87, issue.Suppl 1, pp.637-678, 2006. ,
DOI : 10.1038/sj.bjc.6600466
Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients, British Journal of Cancer, vol.196, issue.1, pp.183-191, 2014. ,
DOI : 10.1007/s12032-012-0226-8
Acute-phase protein response and survival duration of patients with pancreatic cancer, Cancer, vol.72, issue.8, pp.2077-82, 1995. ,
DOI : 10.1038/bjc.1994.93
Evaluation of Modified Glasgow Prognostic Score for Pancreatic Cancer, Pancreas, vol.45, issue.2, pp.211-218, 2016. ,
DOI : 10.1097/MPA.0000000000000446
Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: A meta-analysis, World Journal of Gastroenterology, vol.21, issue.9, pp.2807-2822, 2015. ,
DOI : 10.1038/bjc.2012.292
Clinical implications of systemic inflammatory response markers as independent prognostic factors for advanced pancreatic cancer, Pancreatology, vol.15, issue.2, pp.145-50, 2015. ,
DOI : 10.1016/j.pan.2014.12.004
Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer, Medical Oncology, vol.173, issue.5, pp.3092-100, 2012. ,
DOI : 10.1093/aje/kwq437
Clinical Implication of Inflammation-Based Prognostic Score in Pancreatic Cancer, Medicine, vol.95, issue.18, p.3582, 2016. ,
DOI : 10.1097/MD.0000000000003582
Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma, JOP J Pancreas. 10 mars, vol.13, issue.2, pp.199-204, 2012. ,
Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas, British Journal of Cancer, vol.221, issue.2B, pp.21-24, 2005. ,
DOI : 10.1097/00000658-199506000-00011
A Prospective Comparison of the Prognostic Value of Tumor- and Patient-Related Factors in Patients Undergoing Potentially Curative Surgery for Pancreatic Ductal Adenocarcinoma, Annals of Surgical Oncology, vol.88, issue.8, pp.2318-2346, 2011. ,
DOI : 10.1007/s00109-009-0547-z
The Glasgow Prognostic Score as a Predictor of Survival in Patients with Potentially Resectable Pancreatic Adenocarcinoma, Annals of Surgical Oncology, vol.238, issue.1, pp.2917-2940, 2012. ,
DOI : 10.1245/s10434-008-0148-z
Validation of the pretreatment neutrophillymphocyte ratio as a predictor of overall survival in a cohort of patients with pancreatic ductal adenocarcinoma, Pancreas. avr, vol.44, issue.3, pp.471-478, 2015. ,
Preoperative Neutrophil-to-Lymphocyte Ratio (NLR) is Associated with Reduced Disease-free Survival Following Curative Resection of Pancreatic Adenocarcinoma, World Journal of Surgery, vol.129, issue.4, pp.868-72, 2011. ,
DOI : 10.1207/S15327914NC352_2
Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma, The American Journal of Surgery, vol.197, issue.4, pp.466-72, 2009. ,
DOI : 10.1016/j.amjsurg.2007.12.057
Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio, The American Journal of Surgery, vol.200, issue.2, pp.197-203, 2010. ,
DOI : 10.1016/j.amjsurg.2009.08.041
Preoperative platelet to lymphocyte ratio predicts outcome of patients with pancreatic ductal adenocarcinoma after pancreatic resection, Surgery, vol.158, issue.2, pp.360-365, 2015. ,
DOI : 10.1016/j.surg.2015.03.043
Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios, Surgery Today, vol.13, issue.5, pp.583-92, 2016. ,
DOI : 10.1080/13651820701774891
Unresectable pancreatic adenocarcinoma: do we know who survives?, HPB, vol.12, issue.8, pp.561-567, 2010. ,
DOI : 10.1111/j.1477-2574.2010.00220.x
URL : https://doi.org/10.1111/j.1477-2574.2010.00220.x
Cachexia Worsens Prognosis in Patients with Resectable Pancreatic Cancer, Journal of Gastrointestinal Surgery, vol.45, issue.7, pp.1193-201, 2008. ,
DOI : 10.1016/j.ejso.2007.01.022
Definition and classification of cancer cachexia: an international consensus, The Lancet Oncology, vol.12, issue.5, pp.489-95, 2011. ,
DOI : 10.1016/S1470-2045(10)70218-7
Epidemiology of Sarcopenia among the Elderly in New Mexico, American Journal of Epidemiology, vol.147, issue.8, pp.755-63, 1998. ,
DOI : 10.1093/oxfordjournals.aje.a009520
Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image, Journal of Applied Physiology, vol.97, issue.6, pp.2333-2341, 1985. ,
DOI : 10.1038/oby.2003.53
URL : http://jap.physiology.org/content/jap/97/6/2333.full.pdf
Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review, European Journal of Cancer, vol.57, pp.58-67, 1990. ,
DOI : 10.1016/j.ejca.2015.12.030
Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study, The Lancet Oncology, vol.9, issue.7, pp.629-664, 2008. ,
DOI : 10.1016/S1470-2045(08)70153-0
Sarcopenia in an Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic Cancer, Clinical Cancer Research, vol.15, issue.22, pp.6973-6982, 2009. ,
DOI : 10.1158/1078-0432.CCR-09-1525
Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index, PLOS ONE, vol.67, issue.10, p.139749, 2015. ,
DOI : 10.1371/journal.pone.0139749.s003
Impact of Sarcopenia on Outcomes Following Resection of Pancreatic Adenocarcinoma, Journal of Gastrointestinal Surgery, vol.91, issue.4, pp.1478-86, 2012. ,
DOI : 10.3945/ajcn.2010.28608C
Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma: A retrospective cohort study, International Journal of Surgery, vol.39, pp.45-51, 2017. ,
DOI : 10.1016/j.ijsu.2017.01.075
Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective study, Pancreatology, vol.15, issue.6, pp.674-80, 2015. ,
DOI : 10.1016/j.pan.2015.09.008
Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer, Annals of Surgical Oncology, vol.20, issue.31, pp.2416-2439, 2015. ,
DOI : 10.1245/s10434-013-2886-9
Value of preoperative serum CA 19- 9 levels in predicting resectability for pancreatic cancer, Can J Surg J Can Chir. août, vol.49, issue.4, pp.241-245, 2006. ,
High serum CA 19-9 but not tumor size should select patients for staging laparoscopy in radiological resectable pancreas head and peri-ampullary cancer, European Journal of Surgical Oncology (EJSO), vol.41, issue.2, pp.265-274, 2015. ,
DOI : 10.1016/j.ejso.2014.09.006
Borderline resectable pancreatic cancer: More than an anatomical concept, Digestive and Liver Disease, vol.49, issue.2, pp.223-229, 2017. ,
DOI : 10.1016/j.dld.2016.11.010
Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: A systematic review, Pancreatology, vol.15, issue.1, pp.19-24, 2015. ,
DOI : 10.1016/j.pan.2014.11.006
Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer, JAMA, vol.297, issue.3, pp.267-77, 2007. ,
DOI : 10.1001/jama.297.3.267
Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators, Cancer, vol.364, issue.23, pp.5749-56, 2012. ,
DOI : 10.1056/NEJMoa1011923
Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer, Annals of Surgery, vol.261, issue.1, pp.12-19, 2015. ,
DOI : 10.1097/SLA.0000000000000867